/* Hide loading templates */ #js-listings:before, #js-listings:after, .loading-page:before, .loading-page, .loading-page:after, .loading-spinner:before, .loading-spinner:after, body:not(.ember-application):before, body:not(.ember-application):after, /* Hide ui that requires scripting */ #stream_launch_widget, .btn-group { display: none !important; } /* show hidden page elements */ body>#full-page-viewport-wrapper, body>#navigation-menu { display: inherit; } /* show images */ #main img, #series img, #related img { opacity: 1; } /* style warning message */ .noscript-warning { color: #003666; margin: 0 2rem 2rem 2rem; padding: 1.5rem; background: #EBC0B7; border-radius: 5px; } It looks like there's an issue with JavaScript in your browser. For a better experience, we recommend that you enable JavaScript. Go to https://www.whatismybrowser.com/guides/how-to-enable-javascript/ to learn more.

Chris Hansen

Chris Hansen appears in the following:

An End to Gene Patents?

Friday, April 02, 2010

ACLU First Amendment Working Group attorney, Chris Hansen, talks about this week’s New York federal court ruling that declared patents on genes associated with hereditary breast and ovarian cancer invalid. And Nathan Tinker, executive director of the New York Biotechnology Association, explores the ruling's potential impact ...